Discovery of novel pneumococcal surface antigen A (PsaA) inhibitors using a fragment-based drug design approach

ACS Chemical Biology
Megha BajajMatthew A Cooper

Abstract

Streptococcus pneumoniae is a leading cause of life-threatening bacterial infections, especially in young children in developing countries. Pneumococcal infections can be treated with β-lactam antibiotics, but rapid emergence of multidrug-resistant strains of S. pneumoniae over the past two decades has emphasized the need to identify novel drug targets. Pneumococcal surface antigen A (PsaA) is one such target, found on the cell surface of S. pneumoniae. It functions as a high-affinity substrate-binding protein, facilitating acquisition of Mn(2+), which has an important role in protecting S. pneumoniae from reactive oxygen species and, hence, oxidative stress. Consequently, PsaA is essential for bacterial survival and an important virulence factor, which makes it a promising target for antibiotic drug development. To design novel PsaA inhibitors, we used a combination of de novo fragment-based drug discovery and in silico virtual screening methods. We profiled a collection of low molecular weight compounds that were selected based on their structural diversity and ability to bind to apo-PsaA in a virtual docking experiment. The screening resulted in two initial hits that were further optimized by structural variation to improve ...Continue Reading

References

Apr 1, 1990·Clinical Microbiology Reviews·K P Klugman
Jan 1, 1986·The American Journal of Tropical Medicine and Hygiene·F W Denny, F A Loda
Aug 23, 1996·Journal of Molecular Biology·M RareyG Klebe
Jul 1, 1995·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·F Baquero
Aug 22, 2007·Nature Chemical Biology·Anne E ClatworthyDeborah T Hung
Sep 27, 2008·Critical Reviews in Microbiology·Gowrisankar RajamEdwin W Ades
Dec 17, 2008·Drug Discovery Today·Scott D BembenekCharles H Reynolds
Jan 10, 2009·The Pediatric Infectious Disease Journal·Anita K M ZaidiTauseef Ahmed Khan
Feb 24, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir K SahaUNKNOWN Pneumococcal Study Group
Apr 17, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E VaronL Gutmann
May 3, 2011·European Biophysics Journal : EBJ·Nathan SchmidWilfred F van Gunsteren
Nov 11, 2011·PLoS Pathogens·Christopher A McDevittJames C Paton
May 31, 2012·Journal of Computer-aided Molecular Design·Wendy A Warr
Jun 6, 2012·Current Drug Targets·Rafael M CouñagoBostjan Kobe
Nov 12, 2013·Nature Chemical Biology·Rafael M CouñagoChristopher A McDevitt
Feb 1, 2014·Nature Reviews. Drug Discovery·Andrew L HopkinsCharles H Reynolds

❮ Previous
Next ❯

Citations

Dec 1, 2017·PloS One·Natalia D PopowiczY C Gary Lee
Oct 28, 2015·The Journal of Microbiology·Cuong Thach NguyenDong-Kwon Rhee
Mar 31, 2018·Nature Reviews. Microbiology·Jeffrey N WeiserJames C Paton
Mar 28, 2021·Journal of Applied Microbiology·P S Lannes-CostaP E Nagao
Oct 1, 2021·Genes and Immunity·Ann-Kathrin MixChristof R Hauck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.